Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noel Oliveira

Undersea and Hyperbaric Medicine Edinburg, TX Medical Doctor

NPI 1053318311 CMS profile 47679

5509 Doctors Dr, Edinburg, TX 78539

Open in the dashboard

General payments

$32,935

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Noel Oliveira of Edinburg, TX is reported in the CMS Open Payments database as having received $32,935 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $518 16
2024 General $374 17
2023 General $1,924 8
2022 General $2,465 13
2021 General $2,283 33
2020 General $4,883 24
2019 General $20,487 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noel Oliveira
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Noel Oliveira were reported at $518. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Noel Oliveira Undersea and Hyperbaric Medicine median Middle half National median
2019 $20,487 $201 $85–$538 $163
2020 $4,883 $84 $31–$222 $114
2021 $2,283 $138 $52–$383 $132
2022 $2,465 $135 $51–$385 $149
2023 $1,924 $143 $75–$442 $160
2024 $374 $178 $80–$442 $164
2025 $518 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $30,293 165 payments
  2. Osiris Therapeutics Inc. $2,142 21 payments
  3. Stryker Corporation $163 1 payment
  4. KCI USA, Inc $125 1 payment
  5. Organogenesis Inc. $112 1 payment
  6. Abiomed $41 1 payment
  7. Misonix Inc $27 1 payment
  8. Next Science LLC $25 1 payment
  9. Aroa Biosurgery Incorporated $8 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,540 16 payments
  2. Travel and Lodging $5,784 21 payments
  3. Food and Beverage $3,611 156 payments
Products named General payments · program years 2019–2025
  1. GRAFIX XC $22,440 41 payments
  2. Grafix PL PRIME $17,908 46 payments
  3. Grafix CORE $17,747 33 payments
  4. Grafix PRIME $17,722 32 payments
  5. Stravix Other Advanced Wound Management $12,872 56 payments
  6. GRAFIX Other Advanced Wound Management $7,008 41 payments
  7. GRAFIX PL Other Advanced Wound Management $6,709 56 payments
  8. STRAVIX Extremities & Limb Restoration $5,881 10 payments
  9. GRAFIX Other Advanced Wound Management $5,805 8 payments
  10. GRAFIX PL Other Advanced Wound Management $5,007 25 payments
  11. Other $12,986 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

103

Prescriptions dispensed, refills included

Drug cost

$8,132

Paid at the pharmacy, in all

Branded share of claims

37.9%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 18 $7,713
Doxycycline Monohydrate Generic 35 $207
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 21 $116
Doxycycline Hyclate Generic 14 $72
Levofloxacin Generic 15 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$46,457

Medicare's payments for the services billed

Medicare patients

83

Average age 74

Services billed

644

46 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 72%
Chronic kidney disease 59%
Ischemic heart disease 57%
Arthritis 57%
Heart failure 40%
Depression 39%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REGRANEX
  • Smith+Nephew, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record